Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs

British Journal of Clinical Pharmacology

Volumn 62, Issue 4, 2006, Pages 453-456

  Gardiner, Sharon J ^a,b   Gearry, Richard B ^a   Roberts, Rebecca L ^a   Zhang, Mei ^a   Barclay, Murray L ^a   Begg, Evan J ^a  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Azathioprine; Breastfeeding; Pharmacogenetics; Pharmacokinetics

Indexed keywords

6 METHYLTHIOINOSINE; AZATHIOPRINE; DRUG METABOLITE; TIOGUANINE;

ACCURACY; ADULT; ARTICLE; AUTOIMMUNE HEPATITIS; BLOOD ANALYSIS; BREAST FEEDING; BREAST MILK; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG SAFETY; DRUG USE; ERYTHROCYTE; FEMALE; GENOTYPE; HUMAN; INFANT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; MALE; MOTHER; PERINATAL DRUG EXPOSURE; PRIORITY JOURNAL; TREATMENT OUTCOME; WILD TYPE;

6-MERCAPTOPURINE; ADULT; AZATHIOPRINE; BREAST FEEDING; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; METHYLTRANSFERASES; MOTHERS; THIOGUANINE;

EID: 33748744336     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02639.x     Document Type: Article

References (19)

1. Anonymous. The Optimal Duration of Exclusive Breastfeeding. Report of an expert consultation (Document WHO/NHD/01.09). Geneva: World Health Organization 28-30 March 2001. Available online at: http://www.who.int/nut/ (last accessed 14 July 2005).
2. Klement E, Cohen RV, Boxman J, Joseph A, Reif S. Breastfeeding and risk of inflammatory bowel disease: a systematic review with meta-analysis. Am J Clin Nutr 2004; 80: 1342-52.
3. Bennett PN. Drugs and Human Lactation, 2nd edn. Amsterdam: Elsevier 1996.
4. Armenti VT, Mortiz MJ, Davison JM. Drug safety issues in pregnancy following transplantation and immunosuppression: effects and outcomes. Drug Saf 1998; 19: 219-32.
5. Thiagarajan KD, Easterling T, Davis C, Bond EF. Breast-feeding by a cyclosporine-treated mother. Obst Gynecol 2001; 97: 816-8.
6. Grekas DM, Vasiliou SS, Lazarides AN. Immunosuppressive therapy and breast-feeding after renal transplanation. Nephron 1984; 37: 68.
7. Nyberg G, Haljamäe U, Frisenette-Fich C, Wennergren M, Kjellmer I. Breast-feeding during treatment with cyclosporine. Transplantation 1998; 65: 253-5.
8. Coulam CB, Moyer TP, Jiang N-S, Zincke H. Breast-feeding after renal transplantation. Transplant Proc 1982; 14: 605-9.
9. Anonymous. Purinethol. [Prescribing information]. Sellersville, PA: Gate Pharmaceuticals. Available online at http://www.fda.gov/cder/foi/label/2004/ 09053s024lbl.pdf (last accessed 19 July 2005).
10. Gearry RB, Barclay ML, Roberts RL, Harraway J, Zhang M, Pike LS, George PM, Florkowski CM. TPMT and 6-thioguanine nucleotide measurement: early experience of use in clinical practice. Intern Med J 2005; 35: 580-5.
11. Ciulla TA, Sklar RM, Hauser SL. A simple method for DNA purification from peripheral blood. Anal Biochem 1988; 174: 485-8.
12. Roberts RL, Barclay ML, Gearry RB, Kennedy MA. A multiplexed allele-specific polymerase chain reaction assay for the detection of common thiopurine S-methyltransferase (TPMT) mutations. Clin Chim Acta 2004; 341: 49-53.
13. Sies C, Florkowski CM, George PM, Gearry RB, Barclay ML, Harraway J, Pike L, Walmsley T. Measurement of thiopurine methyl transferase activity guides dose-initiation and prevents toxicity from azathioprine. NZ Med J 2005; 118: 1210.
14. National Center for Health Statistics. Clinical Growth Charts. Available online at http://www.cdc.gov/nchs/data/nhanes/growthcharts/ set1clinical/ Cj41c017.pdf (last accessed 19 June 2005).
15. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, Seidman EG. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-13.
16. Schutz E, Gummert J, Mohr FW, Armstrong VW, Oellerich M. Should 6-thioguanine nucleotides be monitored in heart transplant recipients given azathioprine? Ther Drug Monit 1996; 18: 228-33.
17. Nygaard U, Toft N, Schmiegelow K. Methylated metabolites of 6-mercaptopurine are associated with hepatotoxicity. Clin Pharmacol Ther 2004; 75: 274-81.
18. Derijks LJJ, Gilissen LPL, Engels LGJB, Bos LP, Bus PJ, Lohman JJHM, Curvers WL, Van Deventer SJ, Hommes DW, Hooymans PM. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease. Ther Drug Monit 2004; 26: 311-8.
19. Begg EJ, Duffull SB, Hackett LP, Ilett KF. Studying drugs in human milk: time to unify the approach. J Hum Lact 2002; 18: 323-32.